TG Therapeutics Q4 2024 GAAP EPS $0.15, Inline, Sales $108.19M Beat $99.95M Estimate

TG Therapeutics, Inc.

TG Therapeutics, Inc.

TGTX

0.00
TG Therapeutics (NASDAQ: TGTX) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. This is a 250 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $108.19 million which beat the analyst consensus estimate of $99.95 million by 8.24 percent. This is a 146.04 percent increase over sales of $43.97 million the same period last year.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.